Royalty Pharma (RPRX) reported $736 million in revenue for the quarter ended December 2023, representing a year-over-year decline of 30.8%. EPS of $1.15 for the same period compares to $1.56 a year ago.
The reported revenue represents a surprise of +4.71% over the Zacks Consensus Estimate of $702.9 million. With the consensus EPS estimate being $1.03, the EPS surprise was +11.65%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company’s financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock’s price performance.
Here is how Royalty Pharma performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- Royalty Receipts- Growth Products- Cystic fibrosis franchise: $110.53 million versus $234.49 million estimated by two analysts on average.
- Revenue- Royalty Receipts- Growth Products- Tysabri: $22.50 million versus the two-analyst average estimate of $83.28 million.
- Revenue- Royalty Receipts- Growth Products- Imbruvica: $16.39 million versus $61.14 million estimated by two analysts on average.
- Revenue- Royalty Receipts- Growth Products- Xtandi: $15.05 million versus $46.25 million estimated by two analysts on average.
- Revenue- Royalty Receipts- Growth Products- Promacta: $18.76 million versus $54.49 million estimated by two analysts on average.
- Revenue- Royalty Receipts- Growth Products- Trelegy: $60.19 million compared to the $58.39 million average estimate based on two analysts.
- Revenue- Royalty Receipts- Growth Products- Nurtec ODT: $2.72 million versus the two-analyst average estimate of $5.47 million.
- Revenue- Royalty Receipts- Growth Products- Cabometyx/Cometriq: $19.54 million versus $18.60 million estimated by two analysts on average.
- Revenue- Royalty Receipts- Growth Products- Evrysdi: $19.75 million compared to the $32.33 million average estimate based on two analysts.
- Revenue- Royalty Receipts- Growth Products- Trodelvy: $5.01 million versus the two-analyst average estimate of $12.98 million.
- Revenue- Total Royalty Receipts- Growth Products: $451.27 million compared to the $811.34 million average estimate based on two analysts.
- Revenue- Royalty Receipts- Growth Products- Tremfya: $35.27 million versus $37.46 million estimated by two analysts on average.
View all Key Company Metrics for Royalty Pharma here>>>
Shares of Royalty Pharma have returned +7.1% over the past month versus the Zacks S&P 500 composite’s +5.3% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.0% per year. So be sure to give these hand-picked 7 your immediate attention.
Royalty Pharma PLC (RPRX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Image and article originally from www.nasdaq.com. Read the original article here.